Major BCR-ABL transcript (e13a2 or e14a2)
The most common BCR-ABL transcript in chronic myeloid leukemia, used to monitor response.
Parent marker: BCR-ABL
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
Transcript levels are used to assess the depth of response to tyrosine kinase inhibitors, and regular monitoring is part of long-term management.
How this finding appears in a report
Measured by quantitative PCR and reported on an international scale used by laboratories.
When therapy stops working
Elevated transcript levels can indicate treatment resistance or non-adherence and need to be assessed with a doctor.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: BCR-ABL
The presence of BCR-ABL opens up a category of specific tyrosine kinase inhibitors. Transcript levels are also used to monitor the depth of response to therapy.
A negative result does not always mean absent
Summary
- Gen
- BCR-ABL1
- Variant
- BCR-ABL1 e13a2 / e14a2
- Alteration type
- Fusion
- Discussed in
- Leukemia
- Updated
- 2026-09-10
Other names in reports
e13a2, e14a2, major breakpoint
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.